Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738699 | 0.97 | SLC2A1 (0.54) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| Bromide SCHEMBL4940376 | 0.95 | SLC2A1 (0.52) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| Bromide SCHEMBL22749619 | 0.87 | SMN1; SMN2 (0.61) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| Bromide SCHEMBL22749630 | 0.87 | SMN1; SMN2 (0.52) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL22761785 | 0.84 | SMN1; SMN2 (0.55) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL22749443 | 0.84 | SMN1; SMN2 (0.64) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| Bromide SCHEMBL4943678 | 0.82 | CYP1A1 (0.64) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| Bromide SCHEMBL4942000 | 0.82 | SMN1; SMN2 (0.55) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| Bromide SCHEMBL22749631 | 0.82 | SMN1; SMN2 (0.57) | SLC2A1LMNASMN1; SMN2HTTTSHR | |
| Bromide SCHEMBL22749449 | 0.81 | HTT (0.46) | SLC2A1LMNASMN1; SMN2HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251054-A1 | Analogues and Methods of Treating Rett Syndrome | UNIV CALIFORNIA (US) | 2022-08-11 | — | — | US | claimed |
| EP-3976796-A1 | PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME | The Regents of the University of California (US) | 2022-04-06 | — | — | EP | claimed |
| WO-2020247336-A1 | PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-10 | — | — | WO | claimed |
| US-20220251054-A1 | Analogues and Methods of Treating Rett Syndrome | UNIV CALIFORNIA (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3976796-A1 | PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME | The Regents of the University of California (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020247336-A1 | PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251054-A1 | Analogues and Methods of Treating Rett Syndrome | MECP2, PAX3, PAX2 | SLC2A1 4315/4885LMNA 3220/4885SMN1; SMN2 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.